Pfizer COVID-19 vaccine paediatric formulation (5-11 years) COVID-19 vaccines Main navigation COVID-19 vaccines Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Child participants Pfizer bivalent COVID-19 vaccine Moderna COVID-19 vaccine Moderna bivalent COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines National Immunisation Program Schedule vaccines Mpox (monkeypox)vaccine As part of the Australian COVID-19 vaccination program, AusVaxSafety is actively monitoring COVID-19 vaccines currently in use in Australia to ensure their ongoing safety. Vaccine safety surveillance through AusVaxSafety occurs in selected vaccination clinics around Australia, including state vaccination hubs, pharmacies, GPs and Aboriginal Community Controlled Health Organisations. Click on the tiles below to view AusVaxSafety COVID-19 vaccine safety data for individuals who received the paediatric 10 microgram formulation of the Pfizer COVID-19 vaccine. Child participants View COVID-19 vaccine safety data for child participants aged 5-11 years COVID-19 vaccines Main navigation COVID-19 vaccines Pfizer COVID-19 vaccine adult formulation Pfizer COVID-19 vaccine paediatric formulation (5-11 years) Child participants Pfizer bivalent COVID-19 vaccine Moderna COVID-19 vaccine Moderna bivalent COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines National Immunisation Program Schedule vaccines Mpox (monkeypox)vaccine News & events All news & events 26 February 2023 | News What is a bivalent COVID-19 vaccine and how do the short-term side effects compare to the original COVID-19 booster vaccines? 10 February 2023 | News Update to AusVaxSafety COVID-19 vaccine safety data reporting 31 January 2023 | News Short-term adverse event profile of COVID-19 mRNA vaccines in Aussie kids: reassuring data from AusVaxSafety 22 December 2022 | News How common are severe side effects from COVID vaccines? And how are they detected?